Patents by Inventor Michael Manning

Michael Manning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170197991
    Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Application
    Filed: February 2, 2017
    Publication date: July 13, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
  • Publication number: 20170183342
    Abstract: The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 29, 2017
    Inventors: JIANMING BAO, XIAOLEI GAO, SANDRA L. KNOWLES, CHUNSING LI, I, MICHAEL MAN-CHU LO, ROBERT D. MAZZOLA, Jr., DEBRA L. ONDEYKA, ANDREW W. STAMFORD, FENGQI ZHANG
  • Patent number: 9676780
    Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: June 13, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Michael Berlin, Pauline Ting, Gang Zhou, Tao Yu, Christopher Boyce, Joseph Michael Kelly, Jayaram R. Tagat, Junying Zheng, Xianhai Huang, Wei Zhou, Jae-Hun Kim, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Rajan Anand, Qiaolin Deng
  • Patent number: 9550750
    Abstract: This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
    Type: Grant
    Filed: October 2, 2013
    Date of Patent: January 24, 2017
    Assignees: Merck Sharp & Dohme Corp., Elexopharm GMBH
    Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
  • Publication number: 20160304486
    Abstract: This invention relates to indoline compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
    Type: Application
    Filed: June 30, 2016
    Publication date: October 20, 2016
    Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
  • Publication number: 20160214997
    Abstract: The present invention is directed to 2,2-difluorodioxolo compounds that are antagonists of A2A receptor. The present invention is also directed to uses of the 2,2-difluorodioxolo compounds described herein in the potential treatment or prevention of neurological disorders and diseases in which A2A receptor are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds and to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which A2A receptors are involved.
    Type: Application
    Filed: August 25, 2014
    Publication date: July 28, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ali Amjad, Gioconda V. Gallo, Timothy J. Henderson, Rongze Kuang, Yeon-Hee Lim, Michael Man-Chu Lo, Edward Metzger, Manuel de Lera Ruiz, Andrew Stamford, Paul Tempest, Brent Whitehead, Heping Wu
  • Publication number: 20160194330
    Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 7, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Michael Berlin, Pauline Ting, Gang Zhou, Tao Yu, Christopher Boyce, Joseph Michael Kelly, Jayaram R. Tagat, Junying Zheng, Xianhai Huang, Wei Zhou, Jae-Hun Kim, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Rajan Anand, Qiaolin Deng
  • Patent number: 9347311
    Abstract: Provided are systems and methods for ground fault immune data measurement system for electric submersible pumps. A data measurement system coupled to the ESP includes a surface unit coupled to a 3-phase power cable for providing power to a 3-phase motor of the ESP and a downhole unit coupled to the motor of the ESP and located downhole in a well. The downhole unit includes sensor and is configured to generate frequency modulated carrier signals for carrying the sensor data to the surface unit. Each of the frequency modulated carrier signals carries identical sensor data and is modulated to a different frequency. The carrier signals are shunted across the motor windings of the ESP motor and onto the 3-phase power cable via a capacitive coupling. Additionally, another carrier signal carrying control data may be transmitted from the surface unit to the downhole unit.
    Type: Grant
    Filed: July 28, 2013
    Date of Patent: May 24, 2016
    Assignee: Saudi Arabian Oil Company
    Inventors: Jinjiang Xiao, Michael Manning
  • Patent number: 9272987
    Abstract: A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R6 is hydrogen, —OH, —C1-6alkyl, —OC1-6alkyl, aryl, or halogen, or together with R7, forms an oxo group, or together with R7 and the atom to which they are attached, form a 5-7-membered carbocycle ring or a 5-7-membered heterocyclic ring having 1, 2, or 3 heteroatoms, wherein alkyl and aryl are unsubstituted or independently mono-, di-, or tri-substituted with R14; R7 is hydrogen, C1-6alkyl, —CF3, aryl, —O-aryl, —O—C1-6alkyl, —C(O)OC1-6alkyl, —C(R15R16)OH, a 5-7-membered heteroaryl having 1, 2, 3 or 4 nitrogen atoms, or halogen, or together with R6, forms an oxo group, or together with R6 and the atom to which they are attached, form a 5-7-membered carbocycle ring or a 5-7-membered heterocyclic ring having 1, 2, or 3 heteroatoms wherein alkyl, aryl and heteroaryl are unsubstituted or independently mono-, di- or tri-substituted with R14; R12 is hydrogen, C1-6alkyl, or —(CH2)1-2OH, or together with R13 and the nitr
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: March 1, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Lin Yan
  • Publication number: 20150361098
    Abstract: Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 17, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
  • Patent number: 9108920
    Abstract: A compound having the structure: useful for treating hypertension, Pulmonary Arterial Hypertension (PAH), congestive heart failure, conditions resulting from excessive water retention, cardiovascular disease, diabetes, oxidative stress, endothelial dysfunction, cirrhosis, pre-eclampsia, osteoporosis or nephropathy.
    Type: Grant
    Filed: October 25, 2011
    Date of Patent: August 18, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Robert K. Baker, Zhiqiang Guo, Brent Whitehead, Timothy J. Henderson, Edward Metzger, Lin Yan, Shrenik K. Shah, James Dellureficio, Jun Wang
  • Publication number: 20150225365
    Abstract: This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.
    Type: Application
    Filed: October 2, 2013
    Publication date: August 13, 2015
    Applicants: ElexoPharm GmbH, Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Edward Metzger, Lina Yin, Rolf Hartmann, Qingzhong Hu, Ralf Heim, Christina Zimmer
  • Publication number: 20150206241
    Abstract: A method and system for managing and facilitating communications among affiliants to financial instruments that otherwise are precluded from directly and optimally interacting via the Street Name System is provided. More particularly software-based tools are provided that allow immediate, identity-protected responses and dialogued messaging among parties that can be validated with respect to their affiliations when they interact. The platform also allows holder-to-holder communications, which is not currently possible within the Street Name System. It can facilitate interactions among all types of affiliants to a financial instrument whether issuer, holder, lawyer, service provider, or otherwise.
    Type: Application
    Filed: January 21, 2014
    Publication date: July 23, 2015
    Inventors: Michael Manning, David Jefferds
  • Patent number: 9073929
    Abstract: This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: July 7, 2015
    Assignees: ElexoPharm GmbH, Merck Sharp & Dohme Corp.
    Inventors: Scott B. Hoyt, Whitney Lane Petrilli, Clare London, Yusheng Xiong, Jerry Andrew Taylor, Amjad Ali, Michael Man-Chu Lo, Timothy J. Henderson, Qingzhong Hu, Rolf Hartmann, Lina Yin, Ralf Heim, Emmanuel Bey, Rohit Saxena, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
  • Patent number: 9069339
    Abstract: Accurate and reliable techniques for determining a current status of an accessory device in relation to an electronic device are described.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: June 30, 2015
    Assignee: Apple Inc.
    Inventors: Michael A. Cretella, Jr., Venu Madhav Duggineni, Michael Man-Cheung Eng, Ronald Keryuan Huang, Christopher Moore, Christopher T. Mullens
  • Patent number: 8996603
    Abstract: A method is disclosed for determining a whether access to host requested by a user is permitted. User identifying information is obtained using any of a variety of techniques. The method includes determining a user domain, which indicates an identity of the user's home service provider. A list of hosts is determined based on the home provider. If the requested host is in the list of hosts, then the user is allowed access to the requested host though the user is not authorized. The list of hosts may be determined by one or more attributes from an actual or implied user profile, such as a domain name.
    Type: Grant
    Filed: August 16, 2005
    Date of Patent: March 31, 2015
    Assignee: Cisco Technology, Inc.
    Inventors: Chen Yehezkel Burshan, Michael Manning, Elad Goldberg
  • Patent number: 8949676
    Abstract: A method, an apparatus and an article of manufacture for detecting an event storm in a networked environment. The method includes receiving a plurality of events via a plurality of probes in a networked environment, each of the plurality of probes monitoring a monitored information technology (IT) element, aggregating the plurality of events received into an event set, and correlating the plurality of events in the event set to determine whether the plurality of events are part of an event storm by determining if the plurality of events in the event set meet one or more event storm criteria.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: February 3, 2015
    Assignee: International Business Machines Corporation
    Inventors: Michael Man Behrendt, Rafah A. Hosn, Ruchi Mahindru, Harigovind V. Ramasamy, Soumitra Sarkar, Mahesh Viswanathan, Norbert G. Vogl
  • Patent number: D724283
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: March 10, 2015
    Assignee: Techtronic Floor Care Technology Limited
    Inventors: Daragh Michael Manning, Darren David Holmes, Samuel William Bennett
  • Patent number: D774260
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: December 13, 2016
    Assignee: Techtronic Floor Care Technology Limited
    Inventor: Daragh Michael Manning
  • Patent number: D776381
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: January 10, 2017
    Assignee: Techtronic Floor Care Technology Limited
    Inventor: Daragh Michael Manning